Zelboraf: A Guide to Its Uses, Dosages, Demographics, Side Effects, Interactions, and Generic Options Zelboraf is a targeted therapy drug used to treat metastatic or unresectable melanoma that carries BRAF V600 mutations. It belongs to a class of drugs known as BRAF inhibitors and is manufactured by Roche. Uses: Zelboraf is used to treat metastatic or unresectable melanoma that has a specific genetic mutation known as BRAF V600E or V600K. Melanoma is a type of skin cancer that starts in the cells that produce pigment. When melanoma cannot be removed by surgery or has spread to other parts of the body, it is known as metastatic or unresectable melanoma. Zelboraf works by blocking the activity of mutant BRAF protein, which is one of the most common genetic mutations found in melanoma patients. Dosage and Administration: The recommended dosage for Zelboraf is 960 mg twice daily, taken orally with or without food. The treatment should be continued until the disease progression or unacceptable toxicity occurs. The dosage may also be adjusted based on the patients’ individual needs, response to treatment, and medical condition. Demographics: Zelboraf is approved for use in the treatment of metastatic or unresectable melanoma in adults with a specific genetic mutation known as BRAF V600E or V600K. It is not recommended for use in children or pregnant women. Side Effects: Like any other medications, Zelboraf can cause side effects, including: - Skin problems, including rash, dry skin, and photosensitivity - Joint pain, muscle pain, and headaches - Fatigue, fever, and chills - Nausea, vomiting, diarrhea, and loss of appetite - Changes in hair color, vision, and taste - Heart problems, including arrhythmia and heart failure - Lung problems, including pneumonitis and decreased lung function - Increased risk of developing secondary skin cancers, including squamous cell carcinoma and keratoacanthoma - Hemorrhage and increased bleeding risk. Interactions: Zelboraf has the potential to interact with other medications, including: - Strong CYP3A4 inhibitors, such as ketoconazole and itraconazole, may increase Zelboraf's exposure, leading to toxicity and side effects - Strong CYP3A4 inducers, such as rifampin and phenytoin, may decrease Zelboraf's effectiveness - Anticoagulants may increase the risk of bleeding when taken with Zelboraf - QT prolonging drugs may increase the risk of arrhythmia when taken with Zelboraf. Generic options: Zelboraf is marketed under its brand name and does not have any generic versions available in the United States. However, there are other BRAF inhibitors available, including dabrafenib (Tafinlar), vemurafenib (Cotellic), encorafenib (Braftovi), and binimetinib (Mektovi). These drugs work similarly to Zelboraf, but they have different side effects profiles and may interact with other medications differently. Conclusion: Zelboraf is a targeted therapy drug used to treat metastatic or unresectable melanoma carrying BRAF V600 mutations. It works by blocking the activity of mutant BRAF protein, which is one of the most common genetic mutations found in melanoma patients. While Zelboraf is generally well-tolerated, it can cause side effects, including skin problems, joint pain, muscle pain, and headaches. It can also interact with other medications, including strong CYP3A4 inhibitors and inducers, anticoagulants, and QT prolonging drugs. While there are currently no generic versions of Zelboraf available in the United States, there are other BRAF inhibitors that work similarly and may be used as alternative treatment options. As always, patients should consult with their healthcare professionals to determine the best course of treatment for their individual needs.